Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation
Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...
Metsera to Present at TD Cowen’s 45th Annual Health Care Conference
Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced ...
Metsera started by Guggenheim at buy on obesity drug opportunity
Guggenheim has initiated coverage of Metsera (MTSR) with a buy rating, citing the company's obesity drug candidates. Read ...
Metsera initiated with an Outperform at Evercore ISI
Evercore ISI analyst Umer Raffat initiated coverage of Metsera (MTSR) with an Outperform rating. Metsera has a full portfolio of GLP-1 ...
This weight-loss drug stock could deliver a 90% return in 2025
Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...
Metsera initiated with a Buy at BofA
BofA initiated coverage of Metsera (MTSR) with a Buy rating and $38 price target implying over 20% share upside. Metsera is a clinical-stage ...
Why this newly public biotech could become a force in obesity treatments
Metsera’s GLP-1 peptide has a long half-life, meaning it could be administered once a month. The company is ready to scale up ...
pharmaphorum6d
Two more biotechs, Metsera and Maze, cross IPO finish line
Metsera and Maze Therapeutics have become the ... Trading is due to start today on the Nasdaq under the MTSR ticker. Genetic medicines company Maze meanwhile sold 8.75 million shares at $16 ...
pharmaphorum4d
Nine-month-old obesity player Metsera files an IPO
Metsera is leaving no fundraising stone unturned ... to list on the Nasdaq under the 'MTSR' symbol. The filing – given a $100 million placeholder value by Renaissance Capital, but which could ...